Sage Journals: Discover world-class research

Abstract

BACKGROUND

The autoimmune disorder known as Graves’ disease. The condition is due to the binding of thyroid-stimulating immunoglobulins to the thyrotropin receptor located on the thyroid gland. The result is an excess of thyroidal hormones. symptoms of hyperthyroidism, and the formation of diffuse goiter.

OBJECTIVES

This research intends to quantify the levels of CD40L, TSAB in people who suffer from Graves’ disease. It also aims to determine the relationship between TSAB and the duration of the disease, as well as analyze the role of CD40L as a predictive marker for Graves’ disease using medcalc Statistical Software version 16.4.3 and SAS (2018).

METHODS:

In a case-control study, randomly selected 90 graves disease patients were included, the randomly selected patients were divided equally and matched into a case group who have graves disease and graves disease-free patients as a control group. For both groups whole blood sample was examined to compare for (TSAB), and (CD40L) levels determination by ELISA technique.

RESULTS

The average serum levels of CD40L showed a highly significant correlation (P value < 0.01) among the groups examined for Graves’ disease. The patient group consisted of 13 males (28.89%) and 32 females (71.11%). No significant correlation was identified between TSAB and the duration of the condition.

CONCLUSION

Thyroid stimulating antibody (TSAb) test and ultrasonography of the thyroid gland are valuable diagnostic techniques for autoimmune Graves’ disease (GD). CD40L could potentially serve as a predictive diagnostic marker for Graves’ disease. However, there is no observed link between the duration of the disease and the concentration of TSAB.

Keywords

Graves disease hyperthyroidism CD40L TSAb

Get full access to this article

View all access options for this article.

References

Pokhrel

Bhusal

, Graves disease, Nih Gov 20 (2023), 1–13. https://wwwncbi.nlm.nih.gov/books/NBK448195/.

Davies

T.F.

et al., Graves, disease, Nature Reviews Disease Primers 6 (2020), 1–23. doi: 10.1038/s41572-020-0184-y.

Tamer Mohamed Elsherbiny, Characterization, treatment preferences, and outcomes of 390 Egyptian Graves’ disease patients: a retrospective study, The Egyptian Journal of Internal Medicine (Print) 8 (2023), 20–28. doi: 10.1186/s43162-023-00244-x.

Fujita

Koshiba

Abe

Kato

, Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD’s voxel S values in Graves disease, EJNMMI Physics 7 (2020). doi: 10.1186/s40658-020-0274-7.

Kahaly

George J.

Bartalena

Hegedüs

Leenhardt

Poppe

Pearce

Simon H.

, 2018 European thyroid association guideline for the management of Graves hyperthyroidism, European Thyroid Journal 7 (2018), 167–186. doi: 10.1159/000490384.

Vargas-Uricoechea

, Molecular mechanisms in autoimmune thyroid disease, Cells, 12 (2023), 918. doi: 10.3390/cells12060918.

Antonelli

et al., Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy, Best Practice and Research Clinical Endocrinology and Metabolism 34 (2020) Feb, 101388. doi: 10.1016/j.beem.2020..

Choi

Lee

H.-J.

Sohn

H.-J.

Kim

T.-G.

, CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8+ T cells, BMC Immunology 24 (2023). doi: 10.1186/s12865-023-00547-2.

Metcalfe

R.A.

McIntosh

R.S.

Marelli-Berg

Lombardi

Lechler

Weetman

A.P.

, Detection of CD40 on human thyroid follicular cells: analysis of expression and function1, The Journal of Clinical Endocrinology and Metabolism 83 (1998), 1268–1274. doi: 10.1210/jcem.83.4.4732.

10.

Toubi

Shoenfeld

, The role of CD40–CD154 interactions in autoimmunity and the benefit of disrupting this pathway, Autoimmunity 37 (2004), 457–464. doi: 10.1080/08916930400002386.

11.

Goules

Tzioufas

A.G.

Manousakis

M.N.

Kirou

K.A.

Crow

M.K.

Routsias

J.G.

, Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases, Journal of Autoimmunity 26 (2006), 165–171. doi: 10.1016/j.jaut.2006.02.002.

12.

Mysliwiec

Oklota

Nikolajuk

Waligorski

Gorska

, Serum CD40/CD40L system in graves’ disease and hashimoto’s thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response, Immunological Investigations 36 (2007), 247–257. doi: 10.1080/08820130601069715.

13.

Santos

T.D.S.

Oliveira

J.C.

Freitas

de Carvalho

A.C.

, Thyroid-stimulatory antibody as a predictive factor for graves’ disease relapse, Cureus 14 (2022). doi: 10.7759/cureus.22190.

14.

Tong

et al., Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves’ disease, Clinica Chimica Acta 521 (2021), 34–39. doi: 10.1016/j.cca.2021.06.017.

15.

Neumann

Geras-Raaka

Marcus-Samuels

Gershengorn

M.C.

, Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization, The FASEB Journal 24 (2010), 3992–3999. doi: 10.1096/fj.10-161745.

16.

Minich

W.B.

Lenzner

Morgenthaler

N.G.

, Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor, Clinical and Experimental Immunology 136 (2004), 129–136. doi: 10.1111/j.1365-2249.2004.02417.x.

17.

Kahaly

G.J.

et al., A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism – A Proof-of-Concept Trial, The Journal of Clinical Endocrinology and Metabolismb 105 (2019), 696–704. doi: 10.1210/clinem/dgz013.

18.

Smith

T.J.

Hegedüs

, Graves’ Disease, New England Journal of Medicine 375 (2016), 1552–1565. doi: 10.1056/nejmra1510030.

19.

Elgueta

Benson

M.J.

de Vries

V.C.

Wasiuk

Guo

Noelle

R.J.

, Molecular mechanism and function of CD40/ CD40L engagement in the immune system, Immunological Reviews 229 (2009), 152–172. doi: 10.1111/j.1600-065x.2009.00782.x.

20.

Mysliwiec

Oklota

Nikolajuk

Waligorski

Gorska

, Serum CD40/CD40L system in GRAVES’ disease and hashimoto’s thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response, Immunological Investigations 36 (2007), 247–257. doi: 10.1080/08820130601069715.

21.

Metwalley

K.A.

Farghaly

H.S.

Raafat

D.M.

Ismail

A.M.

Saied

G.M.

, Soluble CD40 ligand levels in children with newly diagnosed Graves’ disease, Journal of Clinical Research in Pediatric Endocrinology 12 (2020), 197–201. doi: 10.4274/jcrpe.galenos.2019.2019.0108.

22.

Lee

Kahaly

George J.

, Novel Approaches for Immunosuppression in Graves’ Hyperthyroidism and Associated Orbitopathy, European Thyroid Journal (2020), 1–14. doi: 10.1159/000508789.

23.

Santos

T.D.S.

Oliveira

J.C.

Freitas

de Carvalho

A.C.

, Thyroid-stimulatory antibody as a predictive factor for Graves’ disease relapse, Cureus 14 (2022). doi: 10.7759/cureus.22190.

24.

Kahaly

G.J.

Diana

Kanitz

Frommer

Olivo

P.D.

, Prospective trial of functional thyrotropin receptor antibodies in Graves disease, The Journal of Clinical Endocrinology and Metabolism 105 (2019), e1006–e1014. doi: 10.1210/clinem/dgz292.